ArticleCell and tissue banking2022
The biobank of barretos cancer hospital: 14 years of experience in cancer research.
Article in Cell and tissue banking, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed.
- Neoadjuvant carboplatin in triple-negative breast cancer: results from NACATRINE, a randomized phase II clinical trial.Breast cancer research and treatment · 2023Trial
- Brazilian biorepository to support genome-wide association studies of colorectal, breast, and cervical cancer.iScience · 2026Article
- Comparative evaluation of microRNA detection in plasma, urine and liquid-based cytology for high-grade cervical intraepithelial neoplasia.Oncology letters · 2026Article
- Genomic landscape of pediatric germ cell tumors reveals oncogenic mutations and copy number alterations.Frontiers in oncology · 2026Article
- Exploring shared microRNA profiles in liquid-based cytology and plasma as biomarkers of high-grade intraepithelial lesions.Scientific reports · 2025Article
- Establishment and molecular profiling of a PDX model of a metachronous brain tumor in a patient with constitutional mismatch repair deficiency with biallelic MSH6 variant.Animal models and experimental medicine · 2025Article
- The impact of artificial intelligence on biomarker discovery.Emerging topics in life sciences · 2025Article
- Exploring the Nottingham classification: assessing gene expression profiles in breast cancer patients and their association with outcomes.Breast cancer research and treatment · 2025Article
- Plasma mutation profile of precursor lesions and colorectal cancer using the Oncomine Colon cfDNA Assay.BMC cancer · 2024Article
- Development of a unified method for the determination of legacy and metabolites of current pesticides in serum for exposure assessment.Analytical and bioanalytical chemistry · 2024Article
- EV-miRNAs from breast cancer patients of plasma as potential prognostic biomarkers of disease recurrence.Heliyon · 2024Article
- Cancer inequalities in incidence and mortality in the State of São Paulo, Brazil 2001-17.Cancer medicine · 2023Article
- Combined SEPT9 and BMP3 methylation in plasma for colorectal cancer early detection and screening in a Brazilian population.Cancer medicine · 2023Article
- Article
- Genomic profile of two Brazilian choroid plexus tumors by whole-exome sequencing.Cold Spring Harbor molecular case studies · 2023Article
- The Barretos Cancer Hospital Animal Facility: Implementation and Results of a Dedicated Platform for Preclinical Oncology Models.Veterinary sciences · 2022Article
- Cutaneous and acral melanoma cross-OMICs reveals prognostic cancer drivers associated with pathobiology and ultraviolet exposure.Nature communications · 2022Article
- Somatic targeted mutation profiling of colorectal cancer precursor lesions.BMC medical genomics · 2022Article
- A Research Protocol for a Phase II Single-Arm Clinical Trial Assessing the Feasibility and Efficacy of Neoadjuvant Anastrozole in Patients With Luminal Breast Cancer and Low Proliferative Index: The ANNE Trial.Cancer control : journal of the Moffitt Cancer CenterArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Despite the developments in cancer research over years, cancer is still one of the leading causes of death worldwide. In Brazil, the number of cancer cases for the several next years (2020-2022) is expected to increase up to 625,000. Thus, translational research has been vital to determine the potential risk, prognostic, and predictive biomarkers in cancer. Therefore, Barretos Cancer Hospital implemented a biobank (BB-BCH) in 2006, which is responsible for processing, storage, and provision of biological materials from cancer and non-cancer participants. Hence, this article aimed to describe BB-BCH's history, experiences, and outcomes and explore its impact on Brazilian translational oncology research scenario. BB-BCH has a multidisciplinary team who are responsible for guaranteeing the quality of all processes as recommended by international guidelines for biobanks. Furthermore, BB-BCH has ample equipment to ensure the quality of all material requested by researchers as genetic material (DNA and RNA) and/or entire biospecimens. From 2006 to 2019, BB-BCH contained 252,069 samples from 44,933 participants, the whole collection is represented by 15 different types of biospecimens collected from them. According to our data, the most collected and stored topography in men is head and neck (29%); in women is breast (28%); and in children is torso and limb (27%) samples. Finally, we supported national and international consortia and projects such as The Cancer Genome Atlas. BB-BCH is a vital knowledge source for scientific community, enabling the development of high-quality studies, with a wide variety of tumor categories and high national representativeness of Brazilian population.
Indexed as
Identifiers
34216325What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.